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Chondrogenic differentiating mesenchymal stem cells (MSCs) are mimicking embryonal endochondral ossification and become
hypertrophic. BMP (bone morphogenetic protein) and Activin Membrane Bound Inhibitor (BAMBI) is a pseudoreceptor that
regulates the activity of transforming growth factor-𝛽 (TGF-𝛽) and BMP signalling during chondrogenesis. Both TGF-𝛽 and
BMP signalling are regulators of chondrogenic cell differentiation. Human bone marrow derived MSCs were chondrogenically
predifferentiated in aggregate culture for 14 days. Thereafter, one group was subjected to hypertrophy enhancing media conditions
while controls were kept in chondrogenic medium until day 28. Histological evaluation, gene expression by PCR, and Western
blot analysis were carried out at days 1, 3, 7, 14, 17, 21, and 28. A subset of cultures was treated with the BMP inhibitor Noggin to
test for BMP dependent expression of BAMBI. Hypertrophic differentiated pellets showed larger cells with increased collagen 10
and alkaline phosphatase staining. There was significantly increased expression of BAMBI on gene expression and protein level
in hypertrophic cultures compared to the chondrogenic control and increased BMP4 gene expression. Immunohistochemistry
showed intense staining of BAMBI in hypertrophic cells. BAMBI expression was dose-dependently downregulated by Noggin.
The pseudoreceptor BAMBI is upregulated upon enhancement of hypertrophy in MSC chondrogenic differentiation by a BMP
dependent mechanism.
1. Introduction
The healing capacity of cartilage is very limited and therefore
various tissue engineering approaches have been investigated
to create pheno- and genotypically stable articular cartilage.
Mesenchymal stem cells (MSCs) are promising candidates
for the use of cell based tissue engineering applications.
The chondrogenic potential of MSCs has been shown in
different matrix-free and matrix based cell culture systems
[1–5]. However, chondrogenic differentiating MSCs express
markers like collagen type X, alkaline phosphatase (ALP),
andMMP-13 [6–11], indicating hypertrophic conversion.This
behaviour of chondrogenic differentiating MSCs mirrors the
developmental pathway of growth plate chondrocytes during
endochondral ossification. Additional characteristics of ter-
minal differentiation like vascular invasion andmatrix calcifi-
cation have also been observed after in vivo transplantation of
human chondrogenic MSC pellet cultures into mice [12, 13].
This hypertrophic conversion of chondrogenic differentiating
MSCs raises concerns for a tissue engineering application of
MSCs in articular cartilage repair. It is important to better
understand the mechanisms that regulate late differentiation
steps in chondrogenic differentiating MSCs to find ways to
inhibit hypertrophy. The similarity of MSC chondrogenesis
and embryonic endochondral ossification indicates that sim-
ilar mechanisms are involved in both biological processes
[14]. The different steps of endochondral bone development
are regulated by a number of signalling molecules including
bone morphogenetic proteins (BMPs), transforming growth
factor-𝛽 (TGF-𝛽), fibroblast growth factors (FGFs), parathy-
roid hormone-related peptide (PTHrP), Indian hedgehog
(Ihh), and Wnts (Wingless-related integration sites) [15, 16].
The TGF-𝛽 superfamily consists of signalling molecules
including TGF-𝛽, BMPs, activins, inhibins, and growth and
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differentiation factors (GDFs). These growth factors have
been implicated in the regulation of various processes during
embryonic development including cell growth and differen-
tiation, pattern formation, and tissue specification [17, 18].
BMPs form a subgroup within the TGF-𝛽 superfamily.
BMPs are dimeric proteins and more than 20 BMP related
proteins have been characterized. In the main signalling
pathway, BMPs bind to a heterodimeric receptor complex
composed of type I and type II serine/threonine kinase
receptors [19, 20]. Upon ligand binding, type II receptor
phosphorylates type I receptor.
Thepseudoreceptor BAMBI (BMPand activinmembrane
bound inhibitor) is a transmembrane protein with structural
similarity to type I receptors of the TGF-𝛽 superfamily but
has a shorter intracellular domain. Lack of this intracellular
serine/threonine kinase domain precludes enzymatic activity
[21, 22]. BAMBI inhibits TGF-𝛽 andBMP signalling by block-
ing the interaction between type I and type II receptors [21].
Further on BAMBI is tightly coexpressed with BMP4 during
embryonic development and may act as a negative feedback
regulator of BMP signalling [21, 22]. BMP4 induction has
been shown to be an important factor in the enhancement
of hypertrophy in MSC chondrogenesis [23]. Finally, BAMBI
mediates a considerable degree of crosstalk between the BMP
signalling pathway and TGF-𝛽 signalling pathways.
Interestingly Chen et al. [24] found no developmental
defects in mice lacking alleles for BAMBI. These transgenic
mice were viable and fertile and did not show discernible
developmental defects [24]. In contrast Guillot et al. [25]
found swollen cells in myocardial and glomerular capillaries
in BAMBI deficient mice. Most importantly in respect of
limb development and the role of BAMBI in terminal differ-
entiation of growth plate chondrocytes, Montero et al. [26]
described the role of BAMBI during limb morphogenesis.
Upon repression of BAMBI expression by activin, an increase
in SMAD 1, 5, and 8 could be observed, which was followed
by formation of ectopic cartilage.
Therefore this study was set up in order to investigate
the expression pattern and possible downstream effects of
BAMBI in late stage chondrogenesis. We therefore used an
established hypertrophy model [14] in human MSCs using
triiodothyronine aswell as a refined hypertrophymodel using
BMP4 [23] for hypertrophic conversion of chondrogenically
differentiated MSCs.
2. Material and Methods
2.1. Isolation of MSCs. Upon approval by the local ethics
committee and written consent by the donors human MSCs
were isolated from iliac crest bone marrow aspirates of seven
male patients, aged 21 to 42 years, undergoing surgery that
required autologous bone grafting from the iliac crest. MSCs
were isolated by Ficoll (Biochrom) gradient centrifugation
followed by polystyrene adhesion. Cells were expanded in
Dulbecco’s Modified Eagle’s Medium (DMEM) low glucose
(Invitrogen) with 10% fetal calf serum (PAN Biotech GmbH)
and 1% penicillin/streptomycin (Invitrogen) at 37∘C with 5%
CO
2
. Growth medium was changed twice a week and cells
were trypsinized at 80% confluence and frozen for later use
in liquid nitrogen. After thawing and monolayer expansion,
cells were used for the experiments at passage 1.
2.2. Chondrogenic Differentiation and Enhancement of
Hypertrophy. For differentiation experiments MSCs were
trypsinized and seeded inV-bottomed 96-well polypropylene
plates at 200,000 cells per well in order to form 3D aggregates.
Aggregates were assembled by centrifugation at 250×g for
5min and chondrogenically differentiated in standard chon-
drogenic medium (chon) containing DMEM with high glu-
cose (Invitrogen), 1% ITS (Sigma Aldrich), 50 𝜇g/mL ascor-
bate-2-phosphate (Sigma Aldrich), 40 𝜇g/mL L-proline
(Sigma Aldrich), 100 nM dexamethasone (Sigma Aldrich),
1mM sodium pyruvate (Invitrogen), and 10 ng/mL TGF-𝛽1
(R&D Systems).
Aggregates were predifferentiated for 14 days. Medium
conditions were then changed and aggregates were dis-
tributed in five different groups: (1) standard chondrogenic
medium (chon); (2) chondrogenicmediumwithBMP4 (chon
+ BMP); (3) standard hypertrophy enhancing medium (chon
without TGF-𝛽 and without dexamethasone, including 1 nM
triiodothyronine (T3) (Sigma Aldrich) (hyp)); (4) hypertro-
phy enhancing medium without T3 (hyp − T3); (5) hyper-
trophy enhancing medium with BMP4 instead of T3 (hyp −
T3 + BMP; BMP4 was used at 100 ng/mL) (Figure 1).
In order to test for BMP4 dependent regulation of
BAMBI, the BMP inhibitor Noggin was employed at
10 ng/mL and 100 ng/mL from day 1 in aggregates treated by
hyp − T3 + BMP protocol (Figure 1).
Aggregates were harvested at d1, d3, d7, d14, d17, d21, and
d28 for gene expression analysis.
2.3. Histology. Aggregates for histological analysis were har-
vested on d14 and d28, fixed in 4% paraformaldehyde. 10𝜇m
thick frozen sections were cut on a cryomicrotome (HM
500 OM Cryostat; Microm, Berlin, Germany). Sections were
stained with 1,9-dimethylmethylene blue (DMMB) (Sigma
Aldrich) for sulphated glycosaminoglycans (GAGs).
2.4. Histochemistry and Immunohistochemistry. For histo-
chemical investigations 10 𝜇m thick sections were prepared
as well. Histochemical ALP staining was performed with an
alkaline phosphatase kit (Sigma Aldrich) with neutral red as
counterstain.
For immunohistochemistry mouse anti-BAMBI (1 : 10,
eBioscience), rabbit anti-BMP4 (1 : 250, Abcam), mouse anti-
collagen type X (1 : 20, Quartett Immunodiagnostika und
Biotechnologie GmbH), and mouse anti-collagen type II
(1 : 100, Calbiochem) antibodies were used and immunohis-
tochemistry was carried out as follows: after rinsing samples
in washing buffer for 5 minutes blocking of endogenous
peptidases (3% H
2
O
2
/10% methanol in PBS) was performed
for 30 minutes. Then sections were incubated in blocking
buffer (10% fetal bovine serum/10% goat serum in PBS) for 60
minutes at RT followed by incubation anti-BAMBI primary
antibody in blocking buffer overnight at 4∘C. Immunolabel-
ing was detected by a biotinylated secondary antibody (1 : 100;
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Table 1
Gene Sequence (forward) Sequence (reverse) Concentration
HPRT CGAGATGTGATGAAGGAGATGG GCAGGTCAGCAAAGAATTTATAGC 150 nM
BAMBI CGATGTTCTCTCTCCTCCCAG AATCAGCCCTCCAGCAATGG 150 nM
Chondrogenic (chon)
Hypertrophic (hyp)
Pr
ed
iff
er
en
tia
tio
n 
(c
ho
n)
(d
ay
s 1
–1
4)
Chondrogenic + BMP4
(chon + BMP)
Hypertrophic − T3 (hyp − T3)
PCR at days 1, 3, 7,
14, 17, 21, 28
Hypertrophic − T3 + BMP4
(hyp − T3 + BMP4)
Hypertrophic − T3 +
BMP4 + Noggin (10ng/mL)
Hypertrophic − T3 +
BMP4 + Noggin (100ng/mL)
Histology at days 14
& 28
Western blot at days
1, 7, 14, 21, 28
Figure 1: Schematic of groups and treatments: left bar shows
chondrogenic predifferentiation in TGF-𝛽 containingmedium from
days 1–14.Midline bars show treatment of groups after chondrogenic
predifferentiation from day 14 to day 28. Right column shows
outcome measurements in regard of time points. Overall culture
duration after expansion was 28 days.
Dianova), horse reddish peroxidase conjugated streptavidin
(Vector Laboratories, Burlingame), and metal enhanced
diaminobenzidine as a substrate (Sigma Aldrich).
2.5. RNA Isolation, cDNA Synthesis, and Gene Expression
Analysis. For each of the 7 different independent donors 8 to
10 aggregates per condition and time point were pooled for
the experiments, homogenized in 1mL TRI Reagent (Sigma
Aldrich) using the Power Gen 1000 homogenizer (Fischer
Scientific), and RNA was isolated by the Trizol method.
Reverse transcription was performed with Transcriptor First
Strand cDNA Synthesis kit (Roche). Semiquantitative real-
time PCR was performed with Brilliant SYBR Green QPCR
mix (Stratagene) and the Mx3000P QPCR System (Strata-
gene). Gene expression was normalized to hypoxanthine
guanine phosphoribosyltransferase (HPRT).
For real-time PCR the primers in Table 1 were used.
2.6. Western Blot Analysis. For Western blot analysis, the
following antibodies were used: mouse anti-BAMBI (1 : 1000,
eBioscience) and rabbit anti-𝛽 actin (1 : 10000, Abcam).
5 to 8MSC pellets per time point and per condition
for each patient were pooled, washed in ice cold PBS, and
homogenized in 500 𝜇L 6M urea/2% SDS solution contain-
ing a protease inhibitor cocktail (Sigma) and a phosphatase
inhibitor (Sigma) using the Power Gen 1000 homogenizer
(Fischer Scientific). The lysate was centrifuged for 5 minutes
at 1000×g (4∘C) and the supernatant was transferred to a
new tube. The protein concentration of the supernatant was
determined using the BCA Protein Assay kit (Biorad, DC
Protein Assay) according to the manufacturer’s instructions.
Lysates were supplemented with 4x LDS sample buffer
(Invitrogen) and 10mM dithiothreitol (DTT) and proteins
were denatured for 5minutes at 95∘C. For gel electrophoresis,
equal amounts of protein (10 𝜇g) were loaded and separated
on a 4–12%Bis-Tris Gel (Novex by Life Technologies) at 120V.
After gel electrophoresis proteins were transferred from the
gel to polyvinylidenfluoride (PVDF) membrane (Millipore).
Blotting was performed for 2 hours at 100V. After transfer,
the membrane was blocked for 1 hour in 5% skim milk
powder in Tris buffered saline with Tween 20 (TBST). The
membrane was then incubated in primary antibody in 5%
skim milk powder in TBST over night at 4∘C. The next day,
the membrane was washed three times for 10 minutes in
TBST and afterwards incubated in HPR-coupled secondary
antibody (1 : 1000, Pierce) in 5% skim milk powder in TBST
at room temperature for 1 hour. The membrane was washed
three times in TBST for 10minutes. Chemoluminescence was
detectedwith the ECLwestern kit (Pierce) and by using X-ray
sensitive films (ECL Hyperfilm, Amersham). The films were
developed in a photo developer (Curix 60, AGFA).
Western blot membranes were stripped using ReBlot Plus
(Millipore) according to manufactures instructions.
2.7. Statistical Analysis. Gene expression was analysed by
calculating themeans of every relative expression normalized
to the housekeeping gene HPRT. After check for normal
distribution by Kolmogorov-Smirnov testing two-tailed Stu-
dent’s 𝑡-test was used. To maintain an overall 𝑝-level of 𝑝 <
0.05, post hoc Bonferroni testing was carried out.
3. Results
3.1. Induction of Hypertrophy. Induction of hypertrophy was
achieved by addition of T3 andwithdrawal of dexamethasone
after chondrogenic predifferentiation. The enhancement of
hypertrophy was shown by an increased cell size, stronger
collagen type X staining, and higher ALP activity under
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prohypertrophic conditions compared to standard chon-
drogenic conditions. Extracellular matrix analysis revealed
poorer glycosaminoglycan content (Figures 2(a) and 2(b)).
Immunohistochemically we observed equal to less collagen
type 2 staining (Figures 2(c) and 2(d)) and analysis for hyper-
trophic markers showed increased collagen type 10 staining
(Figures 2(e) and 2(f)) as well as strongly increased staining
for the preapoptotic marker alkaline phosphatase (Figures
2(g) and 2(h)) for samples after hypertrophic conversion
compared to nonconverted samples. These findings are in
line with previously described characteristics of hypertrophic
chondrocytes found in the growth plate [5, 14, 27], allowing
using this hypertrophymodel for further analysis. Both colla-
gen type 2 and type 10 expression increases over time in both
groups without significant difference between the groups
(Supplementary Figure 1 in SupplementaryMaterial available
online at http://dx.doi.org/10.1155/2016/2685147). This is not
concordant with the immunohistochemical results, which
show higher collagen type 10 deposition in the hypertrophic
group. This is a known phenomenon in this model and
has also been discussed in previous papers [14]. The reason
for this discrepancy is that we are dealing with mixed
cell populations and not all cells respond to the switch to
hypertrophy enhancing medium to the same extent. While
some cells undergo hypertrophic differentiation, the TGF-𝛽
withdrawal may lead to dedifferentiation in other cells. This
heterogeneous response can explain the missing significant
difference in gene expression levels.
3.2. Gene Expression of BAMBI Is Increased uponHypertrophic
Conversion. Real-time PCR analysis of BAMBI revealed
a pronounced increase in BAMBI gene expression under
hypertrophic (hyp) conditions compared to chondrogenic
(chon) conditions. BAMBI gene expression is significantly
upregulated at day 17, day 21, and day 28 in hypertrophic
stimulated MSC pellets compared to chondrogenic pellets
(Figure 3(a)). Similarly gene expression of BMP4 is also
upregulated in hypertrophic conditions and reaches sig-
nificant difference compared to chondrogenic conditions
(Figure 3(b)). All gene expressions were normalized to the
housekeeping gene HPRT.
To confirm this result on protein level we performed
Western blot analysis for BAMBI on days 21 and 28. Again,
in hypertrophic stimulated MSC pellets strong signals for
BAMBI protein could be detected, while under chondrogenic
conditions no signal was found. Remarkably, neither BAMBI
gene expression nor BAMBI protein levels changed signifi-
cantly under chondrogenic conditions throughout the whole
time course of our experiment.
3.3. Immunohistochemical Staining of BAMBI Is Increased
upon Hypertrophic Conversion. To further prove the increase
of BAMBI expression, immunohistochemistry for BAMBI
protein was performed.Thereby we also looked for the intra-
cellular distribution of BAMBI protein. Immunohistochem-
istry revealed increased staining for BAMBI in hypertrophic
aggregates compared to chondrogenic aggregates on day 28
(Figure 4). In terms of intracellular distribution of BAMBI,
we observed pronounced staining of the cell membranes
(black arrows, Figure 4). As BAMBI is a membrane bound
protein this finding was expected and confirms the presence
of BAMBI protein within the cells’ membranes.
3.4. Gene Expression of BAMBI Is Induced by BMP4. To fur-
ther investigate the role of BAMBI in the induction of hyper-
trophy, we analysed the expression of BAMBI after BMP4 and
Noggin treatment. It was previously shown that induction of
hypertrophy by T3 and withdrawal of dexamethasone and
TGF-𝛽 is mediated by BMP4 [23]. This is also revealed by
increased BMP4 protein staining in hypertrophically con-
verted groups compared to chondrogenic controls (Figure 5).
Therefore we suggested that similar expression patterns for
BAMBI are achieved upon hypertrophic conversion by BMP4
(Hyp − T3 + BMP).
BMP4 treatment significantly increases BAMBI expres-
sion on day 28 under chondrogenic conditions (nonsignif-
icant increase on day 21). Under hypertrophic conditions
BAMBI expression is significantly increased in MSC pellets
that were treated with BMP4 compared to hypertrophic
medium without T3 (hyp − T3) (Figure 6). In comparison
to hypertrophic medium with T3 (hyp), we only could detect
nonsignificantly increased gene expression levels uponBMP4
treatment (hyp − T3 + BMP) on day 21 but not day 28
(Figure 6). Both conditions, hyp and hyp−T3+BMP, showed
higher levels of BAMBI gene expression compared to BMP4
treatment under chondrogenic conditions.
3.5. Gene Expression of BAMBI Is Downregulated by BMP
Inhibition. According to these findings we further inves-
tigated whether these BAMBI expression patterns can be
avoided by addition of the BMP inhibitor Noggin to hyper-
trophic (hyp) conditions. In order to estimate whether this
inhibition was dose dependent we used two different doses of
Noggin (10 and 100 ng/mL). For controls we added the same
doses to chondrogenic controls.
Treatment with the BMP inhibitor Noggin does not alter
BAMBI expression under chondrogenic conditions on day
21 and day 28. Under hypertrophic conditions, addition of
100 ng/mLNoggin significantly decreases BAMBI expression
on day 21 and day 28 compared to hyp-conditions (Figure 7).
However, decrease of BAMBI expression upon addition
of 10 ng/mL Noggin is only significant on day 21, when
compared to hyp-conditions. Besides the fact that BAMBI
expression is downregulated under hypertrophic conditions
and concurrent addition of the BMP inhibitor Noggin we
could also show that this downregulation is dose dependent.
4. Discussion
4.1. Induction of Hypertrophy. Human MSCs are able to
differentiate into a chondrogenic lineage. However some
hypertrophic markers are expressed nevertheless, whether in
short term culture or long term culture [28]. According to
these findings it has been shown that cultured chondrogenic
MSCs follow the intrinsic pathway of growth plate chon-
drocytes [12] and therefore inevitably become hypertrophic.
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 2: Differences in glycosaminoglycan content shown by DMMB staining of cell pellets after chondrogenic (chon) (a) and hypertrophic
(hyp) conditions (b), as well as different collagen 2 production as revealed by immunohistochemistry against collagen 2 of cell pellets
after chondrogenic (c) and hypertrophic conditions (d). Enhancement of hypertrophy shown by immunohistochemistry against collagen
10 between chondrogenic (e) and hypertrophic (f) conditioned cell pellets as well as by ALP staining of chondrogenic (g) and hypertrophic
(h) conditioned cell pellets. Scale bar = 500 𝜇m.
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Figure 3: (a) Gene expression analysis of BAMBI and (b) BMP4 normalized to HPRT in MSC pellet cultures under chondrogenic
and hypertrophy enhancing conditions analysed by real-time PCR. BAMBI and BMP4 are significantly upregulated under hypertrophic
conditions compared to chondrogenic controls on days 17, 21, and 28. 𝑛 = 7 different donors, ∗𝑝 < 0.001. (c) Western blot analysis of BAMBI:
increased amount of BAMBI protein can be detected under hypertrophic conditions on days 21 and 28 compared to chondrogenic conditions.
HypChon
HypChon
Figure 4: Immunohistochemistry for BAMBI. BAMBI staining is increased under hypertrophic conditions compared to chondrogenic
conditions. Pronounced staining at cell membranes is detected especially under hypertrophic conditions (black arrows). Black scale bar
= 200 𝜇m; white scale bar = 50 𝜇m.
This hypertrophic phenotype of chondrogenic differentiated
MSCs can be experimentally enhanced by changing medium
conditions from chondrogenic to hypertrophy enhancing
medium as described previously [12, 14]. This change in
medium conditions includes withdrawal of TGF-𝛽 and
dexamethasone and the addition of the thyroid hormone
T3. Using this in vitro hypertrophy model for MSCs we
could significantly increase the hypertrophic phenotype of
chondrogenic differentiated humanMSCs.The enhancement
of hypertrophy was clearly shown by an increased cell size,
stronger collagen type X staining, and stronger ALP staining
in hypertrophic MSC pellets. Hypertrophic markers are not
exclusively expressed under prohypertrophic conditions but
also under standard chondrogenic conditions even though to
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HypChon
HypChon
Figure 5: Immunohistochemical staining of BMP4 of day 28MSC pellets. BMP4 protein staining is increased under hypertrophy (hyp)
enhancing conditions as compared to chondrogenic (chon) conditions. Black scale bar = 200 𝜇m; white scale bar = 50 𝜇m.
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Figure 6: Gene expression analysis of BAMBI normalized to HPRT
in MSC pellet cultures after BMP4 treatment under chondrogenic
(chon) and hypertrophy (hyp) enhancing conditions analysed by
real-time PCR. BAMBI expression is increased under chondrogenic
and hypertrophic conditions after BMP4 treatment. 𝑛 = 4 different
donors, ∗𝑝 < 0.05.
a lower degree.There are someALPpositive cells in the center
of chondrogenic MSC pellets but ALP activity is mainly
restricted to the periphery of the pellet. It was described
previously that fibroblast-like cells surroundMSC pellets [7].
Based on this finding, we suggest that the ALP positive ring
around the pellet consistsmainly of fibroblast-like cells rather
than hypertrophic chondrocytes. After hypertrophic induc-
tion, areas of cellular hypertrophy as well as dedifferentiated
areas were detected.
4.2. Gene Expression of BAMBI Is Increased uponHypertrophic
Conversion. BAMBI is a transmembrane protein with struc-
tural similarity to TGF-𝛽 and BMP receptor type I but lacks
the intracellular kinase domain [21]. Thus, BAMBI is able to
inhibit both TGF-𝛽 and BMP signalling. BAMBI has been
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Figure 7: Gene expression analysis of BAMBI normalized to HPRT
in MSC pellet cultures after Noggin treatment under chondrogenic
(chon) and hypertrophy (hyp) enhancing conditions analysed by
real-time PCR. Noggin treatment significantly decreases BAMBI
expression under hypertrophic conditions. 𝑛 = 4 different donors,
∗𝑝 < 0.05.
shown to be coexpressed with BMP4 during xenopus and
mouse embryogenesis [21, 22]. Further on BMP4 induces
BAMBI expression through an evolutionary preserved pro-
moter BMP responsive enhancer 7 (Bre7) [29]. Additionally
also TGF-𝛽 is able to enhance BAMBI expression through
SMAD 3/4 signalling [30].
We detected a significant upregulation of BAMBI under
hypertrophic conditions using T3 and withdrawal of dexam-
ethasone and TGF-𝛽 for hypertrophic conversion (Figure 3).
The upregulation was proven for gene expression as well
as on protein level by Western blotting. The final func-
tion of this strong upregulation of BAMBI however is still
unclear. Preferential inhibition of TGF-𝛽 signalling dimin-
ishes the antihypertrophic effect of TGF-𝛽, resulting in
further enhancement of the hypertrophic phenotype. On
the other hand, predominant interaction with BMP receptor
could ameliorate the BMP induced terminal differentiation
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[23] in our prohypertrophic culture conditions. BAMBI may
act as a negative feedback loop to inhibit BMP signalling in
response to increased BMP4 expression.
4.3. Immunohistochemical Staining of BAMBI Is Increased
upon Hypertrophic Conversion. The same observation of
upregulation of BAMBI expression was conducted using
immunohistochemistry (IHC) with primary antibodies
against the BAMBI pseudoreceptor. Particularly the
membrane binding nature of the pseudoreceptor, which
is also known as a transmembrane receptor, was shown
in higher magnifications of IHC. The membrane binding
character was described earlier by several working groups
[21, 31].
4.4. Gene Expression of BAMBI Is Induced by BMP4. To fur-
ther clarify the induction of BAMBI expressionwe conducted
an experiment in which hypertrophic conversion by T3 (hyp)
was compared to hypertrophic conversion by BMP4 (hyp −
T3 + BMP4). As evidenced by PCR BAMBI was increased,
upregulated upon stimulation by BMP4. The induction of
BAMBI expression by T3 is most probably also mediated
by BMP. It was shown in previous works that Noggin and
dorsomorphin as BMP inhibitors are capable of inhibiting
T3 induced hypertrophy [23]. Therefore the effects of T3 on
BAMBI expression will be most likely achieved by enhanced
BMP expression and as a consequence increased BAMBI
expression.
4.5. Gene Expression of BAMBI Is Downregulated by BMP
Inhibition. This hypothesis is further supported by the find-
ing that BAMBI expression in T3 induced hypertrophy is
dose-dependently downregulated upon addition of the BMP
inhibitorNoggin.This crosstalk betweenT3 triggered cell dif-
ferentiation and BMP4 was shown in human MSCs [23] and
chicken embryos [32], while other working groups suggested
BMP2 as main mediator of hypertrophic conversion in chick
limb buds [33].
It is still under discussion which exact temporospa-
tial distribution BAMBI has during limb development and
whether its role is pivotal or not. It seems that BAMBI,
which is a negative regulator of chondrogenesis, might be a
target in order to stabilize the chondrogenic phenotype of
chondrogenically differentiated MSCs.
5. Conclusion
These experiments showed that the expression of the pseu-
doreceptor BAMBI is strongly upregulated under hypertro-
phy enhancing conditions in human MSCs. T3, BMP4, and
Noggin treatment are able to modulate BAMBI expression.
The function of BAMBI is not clear and needs to be
investigated by functional experiments with knockdown and
overexpression of BAMBI in the future.
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